Drug
Iguratimod clinical trials
Also written T-614.
- studies test it
- 22
- open now
- 6
- in phase 3
- 2
- first study started
- 2009
Keep track of what changes. Save the iguratimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 2
- Phase 4
- 9
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 16
Jiangsu Simcere Pharmaceutical Co., Ltd. (5) · Peking University People's Hospital (4) · Qilu Hospital of Shandong University (3) · RenJi Hospital (3) · Peking Union Medical College Hospital (2) · Eisai Co., Ltd. (1) · Xuzhou Medical University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
Often tested with
Tested in the same studies.
Leflunomide (2) · Methotrexate (2) · T 614 (1) · Glucocorticoid (1) · Adalimumab (1) · Hydroxychloroquine (1)
Studies
Open first, then newest update. How each study uses iguratimod is read from its arms, and is right about nine times in ten.
Testing it · 22
- Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHDRecruitingPhase 1/2Xuzhou Medical UniversityNCT06244628Written as Iguratimod
- Treatment Strategies for IgG4-RD Patients With Superficial Organ InvolvementRecruitingNot applicablePeking Union Medical College HospitalNCT05789030Written as glucocorticoid plus iguratimod
- Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITPNot yet recruitingPhase 2Peking University People's HospitalNCT07057778Written as Iguratimod
- The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's SyndromeRecruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT04981145Written as Iguratimod Tablets
- Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid ArthritisRecruitingPhase 4Yanfeng HouNCT06146972Written as Iguratimod
- The Clinical Efficacy of Immunomodulators in RA PatientsRecruitingPhase 4Qilu Hospital of Shandong UniversityNCT05626348Written as Iguratimod
- The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RACompletedPhase 4Qilu Hospital of Shandong UniversityNCT04928066Written as Iguratimod
- The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months TreatmentCompletedPhase 4Qilu Hospital of Shandong UniversityNCT03855007Written as Iguratimod
- The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownPhase 2Peking University People's HospitalNCT05281068Written as Iguratimod
- Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownPhase 2Peking University People's HospitalNCT05302024Written as Iguratimod
- Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)Status unknownPhase 2/3Peking University People's HospitalNCT05216757Written as Iguratimod
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateCompletedPhase 3Eisai Co., Ltd.NCT00965757Written as T-614
- A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.Status unknownPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT04830644Written as Iguratimod
- A Study of Iguratimod in Patients With Active Rheumatoid ArthritisCompletedPhase 4Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01554917Written as Iguratimod
- Iguratimod in Systemic SclerosisStatus unknownNot applicableRenJi HospitalNCT04515706Written as Iguratimod
- The Iguratimod Effect on Lupus Nephritis (IGeLU)Status unknownPhase 2RenJi HospitalNCT02936375Written as Iguratimod
- Iguratimod in Kidney Transplant RecipientsStatus unknownNot applicableThe First Affiliated Hospital with Nanjing Medical UniversityNCT02839941Written as Iguratimod
- Iguratimod as Treatment for Refractory Lupus NephritisStatus unknownNot applicableRenJi HospitalNCT03054545Written as Iguratimod
- Study of Iguratimod in Sjögren's SyndromeStatus unknownPhase 1/2Peking Union Medical College HospitalNCT03023592Written as Iguratimod
- Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid ArthritisStatus unknownPhase 4Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01548001Written as Iguratimod
See all 22 studies that test iguratimod →
Given in every arm · 1 — iguratimod is usual care beside what is tested
Codes
What other systems call iguratimod · ClinicalTrials.gg INT005072
- MeSH (NLM) C519076iguratimodOne source NLM
- UNII (FDA) 4IHY34Y2NVIGURATIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q13575264iguratimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65886IguratimodOne source FDA
- DrugBank DB12233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C519076 | iguratimod | One source NLM |
| UNII (FDA) | 4IHY34Y2NV | IGURATIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q13575264 | iguratimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65886 | Iguratimod | One source FDA |
| DrugBank | DB12233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.